Compare Entegris Inc (ENTG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Incyte Corporation — how do they compare? Entegris Inc trades at $160 (market cap $22.95B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Entegris Inc and Incyte Corporation are close in size by market cap, and Entegris Inc pays a 0.27% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ENTG | INCY | |
|---|---|---|
Market Cap | $22.95B | $24.54B |
Sector | Technology | Health |
52-Week High | $184.00 | $129.93 |
52-Week Low | $68.80 | $81.61 |
Enterprise Value | $26.16B | $20.04B |
Dividend Yield | 0.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG is trading at $161.18, up 11.77% with strong momentum following three consecutive quarterly earnings beats. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI suggests mild overbought conditions. Recent Q2 2026 results exceeded expectations with 11% revenue growth and 42% EPS growth driven by AI-related semiconductor demand. Analyst consensus remains strongly positive with 66.7% buy ratings and a $188.67 price target representing 17% upside potential.
The outlook remains favorable given ENTG's positioning in advanced semiconductor materials, with AI-driven demand providing tailwinds. However, elevated valuation multiples (P/E 75.11) and execution risks in capacity expansion warrant monitoring. The company's improving cash flow generation and strong institutional interest support continued growth, though semiconductor cycle sensitivity presents the primary risk to sustained performance.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
